Hicks Caitlin W, Selvarajah Shalini, Mathioudakis Nestoras, Perler Bruce A, Freischlag Julie A, Black James H, Abularrage Christopher J
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins Hospital, Baltimore, Md.
Center for Surgical Trials and Outcomes Research, Department of Surgery, The Johns Hopkins Hospital, Baltimore, Md.
J Vasc Surg. 2014 Nov;60(5):1247-1254.e2. doi: 10.1016/j.jvs.2014.05.009. Epub 2014 Jun 14.
The cost of care for diabetic foot ulcers is estimated to be more than $1.5 billion annually. The aim of this study was to analyze inpatient diabetic foot ulcer cost changes over time and to identify factors associated with these costs.
The Nationwide Inpatient Sample (2005-2010) was queried using the International Classification of Diseases, Ninth Revision codes for a primary diagnosis of foot ulceration. The primary outcomes were changes in adjusted total hospital charges and costs over time. Multivariable analysis was performed to assess relative increases (RIs) in hospital charges per patient in 2005 vs 2010 adjusting for demographic characteristics, income, comorbidities (Charlson Comorbidity Index ≥3), insurance type, hospital characteristics, diagnostic imaging, revascularization, amputation, and length of stay.
Overall, 336,641 patients were admitted with a primary diagnosis of diabetic foot ulceration (mean age, 62.9 ± 0.1 years, 59% male, 61% white race). The annual cumulative cost for inpatient treatment of diabetic foot ulcers increased significantly from 2005 to 2010 ($578,364,261 vs $790,017,704; P < .001). More patients were hospitalized (128.6 vs 152.8 per 100,000 hospitalizations; P < .001), and the mean adjusted cost per patient hospitalization increased significantly over time ($11,483 vs $13,258; P < .001). The proportion of nonelective admissions remained stable (25% vs 23%; P = .32) and there were no differences in mean hospital length of stay (7.0 ± 0.1 days vs 6.8 ± 0.1 days; P = .22). Minor (17.9% vs 20.6%; P < .001), but not major amputations (3.9% vs 4.2%; P = .27) increased over time. Based on multivariable analysis, the main factors contributing to the escalating cost per patient hospitalization included increased patient comorbidities (unadjusted mean difference 2005 vs 2010 $3303 [RI, 1.08] vs adjusted $15,220 [RI, 1.35]), open revascularization (unadjusted $15,145 [RI, 1.25] vs adjusted $30,759 [RI, 1.37]), endovascular revascularization (unadjusted $17,662 [RI, 1.29] vs adjusted $28.937 [RI, 1.38]), and minor amputations (unadjusted $9918 [RI, 1.24] vs adjusted $18,084 [RI, 1.33]) (P < .001, all).
Hospital charges and costs related to diabetic foot ulcers have increased significantly over time despite stable hospital length of stay and proportion of emergency admissions. Risk-adjusted analyses suggest that this change might be reflective of increasing charges associated with a progressively sicker patient population and attempts at limb salvage. Despite this, the overall incidence of major amputations remained stable.
据估计,糖尿病足溃疡的护理费用每年超过15亿美元。本研究的目的是分析住院糖尿病足溃疡费用随时间的变化,并确定与这些费用相关的因素。
使用国际疾病分类第九版编码,对全国住院患者样本(2005 - 2010年)进行查询,以获取足部溃疡作为主要诊断的病例。主要结局是调整后的总住院费用和成本随时间的变化。进行多变量分析,以评估2005年与2010年每位患者住院费用的相对增加(RI),并对人口统计学特征、收入、合并症(Charlson合并症指数≥3)、保险类型、医院特征、诊断性影像学检查、血管重建、截肢和住院时间进行调整。
总体而言,336,641例患者因糖尿病足溃疡作为主要诊断入院(平均年龄62.9±0.1岁,59%为男性,61%为白人)。2005年至2010年,糖尿病足溃疡住院治疗的年度累计费用显著增加(578,364,261美元对790,017,704美元;P <.001)。住院患者增多(每10万次住院中分别为128.6例对152.8例;P <.001),且每位患者住院的平均调整后费用随时间显著增加(11,483美元对13,258美元;P <.001)。非选择性入院的比例保持稳定(25%对23%;P = 0.32),平均住院时间无差异(7.0±0.1天对6.8±0.1天;P = 0.22)。小截肢比例随时间增加(17.9%对20.6%;P <.001),但大截肢比例无变化(3.9%对4.2%;P = 0.27)。基于多变量分析,导致每位患者住院费用不断上升的主要因素包括患者合并症增加(2005年与2010年未调整的平均差异为3303美元[RI,1.08],调整后为15,220美元[RI,1.35])、开放性血管重建(未调整为15,145美元[RI,1.25],调整后为30,759美元[RI,1.37])、血管腔内血管重建(未调整为17,662美元[RI,1.29],调整后为28,937美元[RI,1.38])和小截肢(未调整为9918美元[RI,1.2个4],调整后为18,他084美元[RI,1.33])(P均<.001)。
尽管住院时间和急诊入院比例保持稳定,但与糖尿病足溃疡相关的医院费用和成本随时间显著增加。风险调整分析表明,这种变化可能反映了与病情逐渐加重的患者群体相关的费用增加以及保肢治疗的尝试。尽管如此,大截肢的总体发生率保持稳定。